- Rexahn Pharmaceuticals’s CEO, Dr. Chang H. Ahn, To present at the Pharmaceutical Society of Korea Annual Meeting in Seoul, Korea
November 1st, 2007 - Rexahn Pharmaceuticals, Inc. To present at the Acumen Biofin 9th Annual Healthcare Conference
October 29th, 2007 - Rexahn Pharmaceuticals, Inc. To Present at the 2007 Robins Healthcare Investor Conference in New York City
September 27th, 2007 - U.S. Patent Granted for Rexahn Pharmaceuticals’ Sexual Dysfunction Compound, ZORAXEL
September 20th, 2007 - Rexahn Pharmaceuticals Receives Key U.S. Patent for Cancer Compound RX-0047
June 29th, 2007 - Rexahn Pharmaceuticals, Inc. Appoints Dr. Freddie Ann Hoffman to the Board of Directors
June 15th, 2007 - Data from Rexahn Pharmaceuticals’ Phase I Trial of RX-0201(Archexin) to be presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
May 30th, 2007 - Rexahn Pharmaceuticals Receives FDA Approval to Initiate a Phase II trial for Archexin in Patients with Renal Cell Carcinoma
May 29th, 2007 - Rexahn Pharmaceuticals, Inc. To Present at the Robins Group Emerging Opportunities Investment Conference in New York City
May 23rd, 2007 - R&D Directions Magazine Names Rexahn’s Leading Cancer Candidate, RX-0201 (Archexin) Among “100 Great Investigational Drugs”
April 5th, 2007 - Rexahn Readies for its Next Step
March 30th, 2007 - Rexahn Pharmaceuticals Engages Catalyst Financial Resources
March 19th, 2007 - Rexahn Awarded Maryland Industrial Partnerships Grant to Develop Targeted Nano-Polymer Cancer Drugs
March 6th, 2007 - Rexahn Signs Agreement with National Institute of Neurological Disorders and Stroke
February 5th, 2007 - Rexahn Partners with NIH Institute on Drug Development
February 5th, 2007 - Monte Jade Names Rexahn Pharmaceuticals 2006 Biotechnology Company of the Year
January 23rd, 2007
2013 - 2012 - 2011 - 2010 - 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003